Skip to main content
  • Saved

made a Post

New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins

Source :

https://www.e-dmj.org/journal/view.php?doi=10.4093/dmj.2022.0198

Angiopoietin-like 3 (ANGPTL3), angiopoietin-like 4 (ANGPTL4), and angiopoietin-like 8 (ANGPTL8) inhibit LPL activity in a coordinated fashion, thereby regulating the plasma TG levels. ANGPTL3 and ANGPTL8 are produced and secreted by the liver, and ANGPTL8 activates ANGPTL3 to inhibit LPL activity in the heart and muscle [ 81, 82].



Conclusion/Relevance: During the past decade, several drugs have been developed for the treatment of dyslipidemia. Inclisiran, a small interfering RNA that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), shows comparable effects to that of PCSK9 monoclonal antibodies. Bempedoic acid, an ATP citrate lyase inhibitor, is a valuable treatment option for the patients with statin intolerance.